Agios Q2 net loss $86.2M, cash $1.7B; CMO retirement, mitapivat NDA submitted

AGIOS PHARMACEUTICALS, INC.

2021-Q2 EPS reported $27.39

Net loss $86.2M vs $90.5M; cash, cash equivalents and marketable securities $1.7B.
R&D expenses $62.0M (up from $54.1M) for start-up costs of Phase 3 trials and regulatory filings.
Completed NDA in U.S. and MAA in EU for mitapivat in adults with PK deficiency.
Chris Bowden to retire as CMO effective Sept 1; Sarah Gheuens to assume role.
Repurchased 10.5M shares for $529M at average price $50.41 per share.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Christopher Bowden

chief medical officer

AGIO · AGIOS PHARMACEUTICALS, INC.

Effective: 2021-09-01
Filed: July 29, 2021, 7:59 PM ET

On July 27, 2021, Christopher Bowden notified the Company of his intention to resign as chief medical officer of the Company, effective September 1, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Bowden resigned as chief medical officer at AGIOS PHARMACEUTICALS, INC..

Action: resigned
Role: chief medical officer

Exact text from the filing

On July 27, 2021, Christopher Bowden notified the Company of his intention to resign as chief medical officer of the Company, effective September 1, 2021.

View on SEC.gov

AGIOS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-21-228150

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.